CARGO Therapeutics, Inc. Common Stock (CRGX) Stock

About CARGO Therapeutics, Inc. Common Stock

CARGO Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering innovative chimeric antigen receptor (CAR) T-cell therapies for patients battling cancer. Its primary therapeutic candidate is CRG-022, an autologous CD22 CAR T-cell product. This therapy is specifically engineered to counteract mechanisms of resistance in B-cell malignancies by targeting CD22, a distinct tumor antigen prevalent in these conditions. The company's pipeline also includes CRG-023, a novel tri-specific CAR T product candidate designed to engage tumor cells through three different B-cell antigen targets. Formerly known as Syncopation Life Sciences, Inc., the company adopted its current name, CARGO Therapeutics, Inc., in September 2022. Established in 2019, CARGO Therapeutics is headquartered in San Mateo, California.

CARGO Therapeutics, Inc. Common Stock is headquartered in US.

CARGO Therapeutics, Inc. Common Stock (CRGX) stock trades at $4.47 with a market capitalization of $216.19M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.59, reflecting a net loss over the last twelve months, price-to-book of 0.91, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.00 and $25.45, and currently trades 82.4% below its 52-week high.

On profitability, CARGO Therapeutics, Inc. Common Stock generates a return on equity (ROE) of -51.69% (negative, reflecting a net loss), return on capital employed of -59.46%.

Official website: cargo-tx.com